Off-label use of maraviroc in clinical practice

被引：10

作者：

Blanco, Jose-Ramon ^{[1
]}

Ochoa-Callejero, Laura ^{[2
]}

机构：

[1] Hosp San Pedro, Ctr Biomed Res La Rioja CIBIR, Infect Dis Area, Logrono, Spain

[2] Ctr Biomed Res La Rioja CIBIR, Oncol Area, Logrono, Spain

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2016年 / 14卷 / 01期

关键词：

CCR5; antagonist; maraviroc; off-label use; CCR5; ANTAGONIST; CHEMOKINE; BLOCKADE; EFFICACY; DISEASE; INTENSIFICATION; ARTHRITIS; CCL5;

D O I：

10.1586/14787210.2016.1100535

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Maraviroc is a first-in-class selective CCR5 antagonist only approved in combination with other antiretrovirals for the treatment of HIV-infection. However, sometimes, off-label prescribing is necessary. In this regard, interesting data have been obtained with maraviroc from studies using murine models. In human daily clinical practice there are many researching areas of interest where CCR5 could play an important role. Nowadays few clinical trials are evaluating maraviroc's role in non-HIV-infected patients but there are many open issues that need to be answered about CCR5 antagonists. In this article we review some of them.

引用

页码：5 / 8

页数：4

共 29 条

[1] The Inflammatory Chemokine CCL5 and Cancer Progression [J].

Aldinucci, Donatella ;

Colombatti, Alfonso .

MEDIATORS OF INFLAMMATION, 2014, 2014

[2] CCR5 as a Treatment Target in Pulmonary Arterial Hypertension [J].

Amsellem, Valerie ;

Lipskaia, Larissa ;

Abid, Shariq ;

Poupel, Lucie ;

Houssaini, Amal ;

Quarck, Rozenn ;

Marcos, Elisabeth ;

Mouraret, Nathalie ;

Parpaleix, Aurelien ;

Bobe, Regis ;

Gary-Bobo, Guillaume ;

Saker, Mirna ;

Dubois-Rande, Jean-Luc ;

Gladwin, Mark T. ;

Norris, Karen A. ;

Delcroix, Marion ;

Combadiere, Christophe ;

Adnot, Serge .

CIRCULATION, 2014, 130 (11) :880-+

[3] Chemokines and Cardiovascular Risk [J].

Aukrust, Pal ;

Halvorsen, Bente ;

Yndestad, Arne ;

Ueland, Thor ;

Oie, Erik ;

Otterdal, Kari ;

Gullestad, Lars ;

Damas, Jan K. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (11) :1909-1919

[4] Inflammation-Induced Hepatocellular Carcinoma Is Dependent on CCR5 in Mice [J].

Barashi, Neta ;

Weiss, Ido D. ;

Wald, Ori ;

Wald, Hanna ;

Beider, Katia ;

Abraham, Michal ;

Klein, Shiri ;

Goldenberg, Daniel ;

Axelrod, Jonathan ;

Pikarsky, Eli ;

Abramovitch, Rinat ;

Zeira, Evelyne ;

Galun, Eithan ;

Peled, Amnon .

HEPATOLOGY, 2013, 58 (03) :1021-1030

[5] Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+T cell recovery and gene expression [J].

Beliakova-Bethell, Nadejda ;

Jain, Sonia ;

Woelk, Christopher H. ;

Witt, Mallory D. ;

Sun, Xiaoying ;

Lada, Steven M. ;

Spina, Celsa A. ;

Goicoechea, Miguel ;

Rought, Steffney E. ;

Haubrich, Richard ;

Dube, Michael P. .

ANTIVIRAL RESEARCH, 2014, 107 :42-49

[6]

Bogunia-Kubik K, 2006, HAEMATOLOGICA, V91, P1628

[7]

Boolell M, 1996, Int J Impot Res, V8, P47

[8] PERSONAL VIEW We need a global system to help identify new uses for existing drugs [J].

Borges, Ricardo .

BMJ-BRITISH MEDICAL JOURNAL, 2014, 348

[9]

Capetti Amedeo F, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P201, DOI 10.1177/1545109710372671

[10] Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice [J].

Cipriani, Sabrina ;

Francisci, Daniela ;

Mencarelli, Andrea ;

Renga, Barbara ;

Schiaroli, Elisabetta ;

D'Amore, Claudio ;

Baldelli, Franco ;

Fiorucci, Stefano .

CIRCULATION, 2013, 127 (21) :2114-+

← 1 2 3 →